Generalized Myasthenia Gravis research hub
21 indexed studies · 10 currently recruiting
- active not recruitingPHASE1, PHASE2
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
This study is looking at a new cell therapy called YTB323 for people with a severe type of myasthenia gravis, a muscle weakening condition. It aims to see if it's safe and effective for patients who haven't responded well to other treatments.
United States · France · Japan - active not recruitingPHASE3
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
This study is looking into a new medicine, ALXN1720, for adults with generalised myasthenia gravis (gMG). We want to see if it's safe and helps improve symptoms for people whose gMG is caused by certain antibodies. It's compared against a dummy treatment.
United States · Argentina · Austria - recruitingPHASE3
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
This study is looking at a new medicine called Remibrutinib for adults with a condition called Generalized Myasthenia Gravis. It compares Remibrutinib to a dummy medicine (placebo) to see how well it works and if it's safe, alongside their usual treatment.
United States · Argentina · Australia - ongoing, recruitingTherapeutic confirmatory (Phase III)
A MULTICENTER, OPEN-LABEL, OUTPATIENT STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF A ZILUCOPLAN AUTO INJECTOR COMBINATION PRODUCT FOR SUBCUTANEOUS SELF-ADMINISTRATION BY STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS
This study is testing a new way for people with a muscle condition called myasthenia gravis to give themselves a medicine called zilucoplan. It checks if the injection device is easy to use and safe, and if patients can give themselves the medicine properly.
Poland - recruitingPHASE3
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
This study is testing a new medicine, cladribine, in pill form for people with a muscle weakening condition called myasthenia gravis. We want to see if it helps and if it's safe compared to a dummy pill. We're also looking at its long-term effects and how the body uses the medicine.
United States · Argentina · Australia - recruitingPHASE2, PHASE3
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
This study is testing a new medicine, efgartigimod PH20 SC, for children aged 2 to 17 with a muscle weakness condition called generalised Myasthenia Gravis. We want to find the best dose and make sure it's safe. Participants will get injections and be monitored.
United States · Belgium · Canada - recruitingPHASE2
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
This study is looking at a new medicine called inebilizumab for children aged 2-17 with a muscle weakness condition called generalized Myasthenia Gravis (gMG). Researchers want to understand how the medicine works in the body and if it's safe.
United States · France · Spain - enrolling by invitationPHASE2, PHASE3
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
This study looks at the long-term safety of two forms of a drug called efgartigimod for children and teenagers with a muscle weakness condition called generalised Myasthenia Gravis (gMG). Participants are those who have previously taken part in other efgartigimod studies.
United States · Belgium · Canada - active not recruitingPHASE3
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
This study is testing new drug combinations, pozelimab and cemdisiran, for adults with a muscle-weakening condition called generalised myasthenia gravis (gMG). It looks at how safe these drugs are and how well they help improve muscle function.
United States · Belgium · Brazil - active not recruitingPHASE3
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
This study is testing a new medicine called iptacopan for people aged 18-85 with a type of muscle weakness called generalized Myasthenia Gravis (gMG). It's compared to a dummy medicine to see if it's safe and helps improve symptoms while continuing usual care.
United States · Argentina · Australia - authorisedPhase I and Phase II (Integrated)- Other
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis
This study is testing a new medicine called Aritinercept for people with a muscle weakness condition called Myasthenia Gravis. Researchers want to see if it's safe, how well it works, and how your body reacts to it over time. This is an early-stage study.
Poland - active not recruitingPHASE3
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
This study is looking at a new medicine called batoclimab for adults with a condition called generalized Myasthenia Gravis (gMG). It wants to see how well it works and if it's safe. Participants will receive batoclimab or a dummy medicine (placebo) to see if it helps relieve their symptoms.
United States · Argentina · Brazil - recruitingPHASE2, PHASE3
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
This study is testing a new medicine, Zilucoplan, for young people with a muscle condition called generalised myasthenia gravis (gMG). We want to understand how it works, if it's safe, and if it helps improve symptoms in children and teenagers.
United States · Italy · Poland - authorisedTherapeutic use (Phase IV)
OCTAGON:A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients with Generalized Myasthenia Gravis Treated with Ravulizumab
This study looks at how well adults with a muscle weakness condition called myasthenia gravis (gMG) can reduce or stop taking steroid medicines (like prednisone) when treated with a new drug called Ultomiris. It checks if they can safely lower their steroid dose without their gMG symptoms getting worse.
Italy · Germany - recruitingPHASE3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
This study is testing a new medicine, IMVT-1402, for adults with a condition called myasthenia gravis. The aim is to see if it's safe and helps improve daily life for those with mild to severe symptoms.
United States · Argentina · Czechia - active not recruitingPHASE3
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
This study is for people with a muscle condition called generalized myasthenia gravis (gMG) who have already been in a zilucoplan trial. It checks how safe and effective zilucoplan is over a longer time, helping us understand its long-term benefits.
United States · Canada · France - active not recruitingPHASE3
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
This study is testing a new medicine called efgartigimod for people with a type of Myasthenia Gravis (MG). It checks how well it works and if it's safe compared to a dummy medicine. Some people will then get the new medicine openly.
United States · Belgium · Canada - enrolling by invitationPHASE3
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
This study looks at the long-term effects of a medicine called Zilucoplan for children and teenagers with a muscle weakness condition called myasthenia gravis. It checks if the medicine is safe and if people can tolerate it well over an extra year.
Italy · Poland · South Korea - recruitingPHASE2, PHASE3
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
This study is testing a new cell therapy called KYV-101 for people with a type of muscle weakness called myasthenia gravis. It aims to see if this therapy, which targets specific immune cells, can help reduce symptoms and improve daily life for patients.
United States · Australia · Brazil - recruitingPHASE2, PHASE3
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
This study is looking at a new treatment called efgartigimod for children and teenagers aged 2 to 18 with a muscle condition called generalized myasthenia gravis (gMG). It will examine how the treatment works in the body and its safety.
United States · Austria · Belgium - authorisedTherapeutic confirmatory (Phase III)
Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab
This study compares two existing treatments, nipocalimab and efgartigimod, for a muscle weakness condition called generalised myasthenia gravis. It aims to see how well they work and if one is better than the other, especially when people switch from one drug to the other.
Austria · Germany · Spain